Holdings of Albireo Pharma Inc. (ALBO) are aligned with the stars

Albireo Pharma Inc. (NASDAQ: ALBO) stock fell -0.90% on Wednesday to $22.11 against a previous-day closing price of $22.31. With 0.11 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.37 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $22.70 whereas the lowest price it dropped to was $21.70. The 52-week range on ALBO shows that it touched its highest point at $37.63 and its lowest point at $16.02 during that stretch. It currently has a 1-year price target of $58.67. Beta for the stock currently stands at 0.81.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALBO was down-trending over the past week, with a drop of -0.50%, but this was up by 10.94% over a month. Three-month performance surged to 19.19% while six-month performance rose 9.62%. The stock lost -11.77% in the past year, while it has lost -5.07% so far this year. A look at the trailing 12-month EPS for ALBO yields -1.89 with Next year EPS estimates of -6.58. For the next quarter, that number is -1.83. This implies an EPS growth rate of 73.70% for this year and 17.00% for next year.

Float and Shares Shorts:

At present, 20.70 million ALBO shares are outstanding with a float of 18.65 million shares on hand for trading. On Oct 13, 2022, short shares totaled 1.76 million, which was 8.95% higher than short shares on Sep 14, 2022. In addition to Mr. Ronald H. W. Cooper as the firm’s CEO, Pres & Director, Mr. Simon Nicolas Reade Harford serves as its CFO & Treasurer.


Institutional Ownership:

Through their ownership of 104.26% of ALBO’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 55.49% of ALBO, in contrast to 43.58% held by mutual funds. Shares owned by individuals account for 19.58%. As the largest shareholder in ALBO with 11.51% of the stake, Federated Global Investment Manag holds 2,258,124 shares worth 2,258,124. A second-largest stockholder of ALBO, Perceptive Advisors LLC, holds 1,939,723 shares, controlling over 9.89% of the firm’s shares. Deep Track Capital LP is the third largest shareholder in ALBO, holding 1,124,421 shares or 5.73% stake. With a 6.75% stake in ALBO, the Federated Hermes Kaufmann Fund is the largest stakeholder. A total of 1,324,024 shares are owned by the mutual fund manager. The Federated Hermes Kaufmann Small C, which owns about 4.56% of ALBO stock, is the second-largest Mutual Fund holder. It holds 895,200 shares valued at 18.37 million. FTIF SICAV – Biotechnology Discov holds 3.18% of the stake in ALBO, owning 623,494 shares worth 12.79 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALBO since 7 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALBO analysts setting a high price target of $68.00 and a low target of $48.00, the average target price over the next 12 months is $57.14. Based on these targets, ALBO could surge 207.55% to reach the target high and rise by 117.1% to reach the target low. Reaching the average price target will result in a growth of 158.44% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ALBO will report FY 2022 earnings on 03/15/2023. Analysts have provided yearly estimates in a range of -$7.45 being high and -$8.54 being low. For ALBO, this leads to a yearly average estimate of -$8.07. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Albireo Pharma Inc. surprised analysts by $0.12 when it reported -$1.92 EPS against a consensus estimate of -$2.04. The surprise factor in the prior quarter was -$0.21. Based on analyst estimates, the high estimate for the next quarter is -$1.86 and the low estimate is -$2.15. The average estimate for the next quarter is thus -$1.99.

Summary of Insider Activity:

Insiders traded ALBO stock several times over the past three months with 0 Buys and 9 Sells. In these transactions, 0 shares were bought while 420,941 shares were sold. The number of buy transactions has increased to 6 while that of sell transactions has risen to 44 over the past year. The total number of shares bought during that period was 108,000 while 434,874 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *

1406

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam